• HMGB1 as an Early Serum Biomarker for Diabetic Nephropathy

  2026-06-09

  A recent quantitative proteomics study identified HMGB1 as a promising serum biomarker for early monitoring of diabetic nephropathy (DN), addressing the limitations of current noninvasive diagnostic methods. The findings highlight the potential of HMGB1 for improved disease stratification and early intervention in DN progression.

• Verteporfin (CL 318952): Workflow Enhancements in PDT & Auto

  2026-06-09

  Verteporfin (CL 318952) enables dual-action experimental workflows in photodynamic therapy and autophagy inhibition, broadening the toolkit for age-related macular degeneration and cancer research. This article delivers protocol optimizations, troubleshooting insights, and integrative analysis of recent senolytic discovery, ensuring robust experimental outcomes with APExBIO-supplied Verteporfin.

• Bedaquiline: Diarylquinoline Antibiotic for Advanced Researc

  2026-06-08

  Bedaquiline stands at the intersection of antimicrobial and anticancer research, excelling as a diarylquinoline antibiotic against multi-drug resistant tuberculosis while uniquely targeting cancer stem cell metabolism. This article unpacks its experimental workflows, protocol optimization, and the latest insights from host-directed therapy research.

• Catalpol’s Multi-Pathway Protection in Cardio-Cerebrovascula

  2026-06-08

  This comprehensive review elucidates catalpol’s multi-faceted protective actions against cardio-cerebrovascular diseases, highlighting its anti-inflammatory, anti-oxidant, and anti-apoptotic mechanisms. The study synthesizes preclinical evidence and mechanistic insights, positioning catalpol as a promising natural agent for cardiovascular research.

• IWP-2: Precision Wnt Production Inhibition in Cancer Researc

  2026-06-07

  IWP-2 is a potent Wnt production inhibitor that empowers researchers to dissect Wnt/β-catenin pathway dynamics with unparalleled specificity. This article delivers actionable workflows, experimental tips, and troubleshooting strategies for deploying IWP-2 in advanced cancer and cell stress studies.

• Poly-GA Induces Tau Pathology via ERK1/2: Insights from FTLD

  2026-06-06

  This study delineates how C9orf72-derived poly-glycine-alanine (poly-GA) drives tau phosphorylation and neuronal death through direct ERK1/2 activation in cellular models. Inhibition of ERK1/2 with U0126 proved effective in reducing both tau pathology and cell death, highlighting a mechanistic link and potential therapeutic target in C9orf72-associated FTLD.

• G-1: Selective GPR30 Agonist for Cardiac and Oncology Models

  2026-06-05

  G-1 (CAS 881639-98-1) is a next-generation selective GPR30 agonist, enabling precise dissection of non-classical estrogen signaling in cardiovascular and oncology research. This guide delivers actionable protocols, troubleshooting insights, and translates novel mechanistic findings into robust experimental workflows.

• Antimycin A4: Dual-Pathway Modulation for Translational Meta

  2026-06-05

  Discover how Antimycin A4’s dual inhibition of ATP-citrate lyase and the mitochondrial respiratory chain advances experimental design, data reproducibility, and mechanistic insight for translational researchers tackling metabolic disease, infectious agents, and systems biology.

• Bifendate (DDB) in Hepatic Lipid Modulation: Translational I

  2026-06-04

  Explore how Bifendate (DDB) uniquely modulates hepatic lipid metabolism and autophagy, with critical protocol guidance and practical insights for liver research. This article delivers scientific depth and differentiation grounded in primary evidence.

• RG108 in Cancer Epigenetics: Mechanistic Depth and Assay Pre

  2026-06-04

  Explore how RG108, a potent DNA methyltransferase inhibitor, enables precise, non-covalent epigenetic gene regulation in cancer research. This article provides a mechanistic perspective and practical assay guidance distinct from existing resources.

• Dual OXPHOS Disruption: Synergy of LRPPRC Inhibition and Das

  2026-06-03

  This study establishes a novel dual-genome strategy to disrupt oxidative phosphorylation (OXPHOS) in cancer cells by combining LRPPRC inhibition with dasatinib. The approach leverages complementary targeting of mitochondrial and nuclear-encoded OXPHOS genes, offering a mechanistically rational framework for more effective, tumor-selective metabolic therapies.

• Protoporphyrin IX as a Photodynamic Compound in Cancer Workf

  2026-06-03

  Protoporphyrin IX is redefining cancer research and diagnostics as a photodynamic compound, offering unique leverage points in ferroptosis modeling and heme biosynthesis studies. Learn how APExBIO's high-purity Protoporphyrin IX enables robust, reproducible protocols and solves persistent workflow challenges.

• Non-Canonical ORF Translation Drives Medulloblastoma Cell Su

  2026-06-02

  Hofman et al. (2024) demonstrate that widespread translation of non-canonical open reading frames (ORFs), especially the ASNSD1-uORF, is essential for survival in childhood medulloblastoma. Their integrative approach using ribosome profiling and CRISPR tiling uncovers novel, actionable elements in pediatric cancer biology with implications for future therapeutic strategies.

• Western Secondary Antibody Dilution Buffer: Optimizing Blott

  2026-06-02

  APExBIO’s Western Secondary Antibody Dilution Buffer streamlines Western blot workflows by minimizing non-specific binding and extending antibody usability. This article unpacks protocol enhancements, troubleshooting, and practical insights that differentiate this buffer in advanced protein detection assays.

• Oteseconazole (VT-1161): Mechanistic Innovations and Future

  2026-06-01

  Explore the scientific basis and clinical potential of Oteseconazole (VT-1161), a next-generation tetrazole CYP51 inhibitor. This in-depth analysis reveals mechanistic advances, differentiates from prior protocols, and highlights implications for antifungal research and Candida infection management.

16277 records 1/1086 page Next 12345 下5页 Last page